Drugs / CS5007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07622524 | Jun 2026 → Jan 2028 expected | cancer | CStone Pharmaceuticals | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | CStone Pharmaceuticals | Regulatory 继全球I期临床于澳洲启动后，CS5007（EGFR/HER3双特异性ADC）IND申请获中国NMPA批准 cstonepharma.com ↗ |
| 2026-04-20 | CStone Pharmaceuticals | Results AACR 2026 | 基石药业发布CS5007（EGFR/HER3 ADC）临床前研究结果 cstonepharma.com ↗
CS5007在体外血浆稳定性测试中表现优异，其稳定性优于DS-8201（德曲妥珠单抗）。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | CStone Pharmaceuticals | 继全球I期临床于澳洲启动后，CS5007（EGFR/HER3双特异性ADC）IND申请获中国NMPA批准 cstonepharma.com ↗ |
| 2026-04-20 | CStone Pharmaceuticals | AACR 2026 | 基石药业发布CS5007（EGFR/HER3 ADC）临床前研究结果 cstonepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS5007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622524 ↗ |
| Target | EGFR | “CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate” NCT07622524 ↗ |
| Target | HER3 | “CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate” NCT07622524 ↗ |